H. Iwata

发表

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.

A. Schneeweiss, S. Loi, L. Molinero, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis

A. Shimomura, K. Tamura, J. Watanabe, 2017, Breast Cancer Research and Treatment.

LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study

G. Curigliano, S. Verma, S. Im, 2021, Annals of Oncology.

LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC

S. Loi, D. Cescon, V. Karantza, 2021, Annals of Oncology.

LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)

J. Huober, O. Trédan, S. Paluch-Shimon, 2022, Annals of Oncology.

212MO AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC)

P. Kaufman, K. Petráková, G. Paux, 2022, Annals of Oncology.

279P Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)

K. Tamura, Young-Ae Park, S. Modi, 2021, Annals of Oncology.

163O Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC)

P. Fasching, M. Rosenlund, M. Janek, 2022, Annals of Oncology.

Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase 3 DESTINY-Breast03 study.

M. Rosenlund, P. Fasching, G. Curigliano, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

236P Subgroup analysis by disease history and prior treatments of patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1)

S. Hurvitz, E. Hamilton, G. Curigliano, 2022, Annals of Oncology.

Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer.

C. Redfern, K. Tamura, Shin-ichiro Takahashi, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

LBA1 Final analysis of the placebo-controlled randomised phase III IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)

Tong Xu, L. Molinero, K. Punie, 2023, ESMO Open.

Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993.

A. Schneeweiss, S. Loi, H. Rugo, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis

A. Shimomura, K. Tamura, J. Watanabe, 2017, Breast Cancer Research and Treatment.